Bank of America
SGMT icon

Bank of America’s Sagimet Biosciences SGMT Stock Holding History

Bank of America’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$229K Buy
43,858
+33,982
+344% +$189K ﹤0.01% 5294
2025
Q4 		$58.5K Sell
9,876
-15,832
-62% -$114K ﹤0.01% 5792
2025
Q3 		$176K Buy
25,708
+15,765
+159% +$128K ﹤0.01% 6345
2025
Q2 		$75.8K Buy
9,943
+4,473
+82% +$18.9K ﹤0.01% 6648
2025
Q1 		$17.8K Sell
5,470
-9,573
-64% -$40.2K ﹤0.01% 6998
2024
Q4 		$67.7K Sell
15,043
-525,394
-97% -$2.66M ﹤0.01% 6542
2024
Q3 		$1.5M Buy
540,437
+45,411
+9% +$140K ﹤0.01% 4775
2024
Q2 		$1.69M Buy
495,026
+237,805
+92% +$1.09M ﹤0.01% 4555
2024
Q1 		$1.39M Buy
257,221
+240,540
+1,442% +$1.73M ﹤0.01% 4704
2023
Q4 		$90.4K Buy
16,681
+3,695
+28% +$17.4K ﹤0.01% 6411
2023
Q3 		$114K Buy
+12,986
New +$173K ﹤0.01% 6199

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of America's SGMT Position: Q1 2026 in Review

Bank of America increased its Sagimet Biosciences (SGMT) stake by 344% in Q1 2026, buying an estimated $189K and bringing the position to 43,858 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #5294.

Bank of America first reported a position in SGMT in Q3 2023 and has held it in 11 quarters since. The position peaked at $1.69M in Q2 2024. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Bank of America held 43,858 shares of Sagimet Biosciences worth $229K as of Q1 2026.
  • Bank of America bought 33,982 Sagimet Biosciences shares in Q1 2026, an estimated $189K.
  • Sagimet Biosciences made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5294 holding.
  • Bank of America first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 11 quarters since.
  • Bank of America's Sagimet Biosciences position peaked at $1.69M in Q2 2024.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.